“Global Drug Discovery Outsourcing market set to grow to $45bn by 2024” says new Visiongain report

16 April 2019
Pharma

Visiongain has launched a new pharma report Global Drug Discovery Outsourcing Market Report : Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening.

While the main factor driving drug discovery outsourcing is the cost-saving benefits, today’s companies are also looking at benefits and opportunities beyond cost savings. Companies are now outsourcing to gain strategic benefits, such as access to innovative technology, faster response time to support and benchmark internal programs, and ongoing process improvements, overall making them more competitive and increasing globalization within the pharmaceutical industry.

The lead analyst of the report commented "A major restraint in the global drug discovery outsourcing market comes from the fact that it is quickly becoming saturated, with many contract research organisations offering poorly differentiated services. Therefore, pharmaceutical companies have a high bargaining power as they have many CROs to choose from and they are likely to make their decisions on the basis of successful previous alliances. Entry into this market is particularly challenging at present.

One of the current trends in the drug discovery market is the increasing diversification of services offered by CROs. In a poorly differentiated market, CROs have needed to differentiate their services from competitors to entice potential clients."

Leading companies featured in the report include Albany Molecular Research (AMRI), Aptuit, LLC, Charles River Laboratories, Inc., Covance, Inc., Cyprotex plc, Domainex, Evotec AG, GenScript, IQVIA (QuintilesIMS) and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever